USRE34698E - Method of producing salinomycin antibiotics - Google Patents

Method of producing salinomycin antibiotics Download PDF

Info

Publication number
USRE34698E
USRE34698E US08/010,786 US1078693A USRE34698E US RE34698 E USRE34698 E US RE34698E US 1078693 A US1078693 A US 1078693A US RE34698 E USRE34698 E US RE34698E
Authority
US
United States
Prior art keywords
salinomycin
salinomycins
acid
give
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/010,786
Inventor
Yukio Miyazaki
Akira Shibata
Tateo Yahagi
Masayuki Hara
Kaoru Hara
Singo Yoneda
Hiroko Kasahara
Yuko Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP52062802A external-priority patent/JPS6038115B2/en
Priority claimed from JP6321577A external-priority patent/JPS53148595A/en
Application filed by Kaken Chemical Co Ltd filed Critical Kaken Chemical Co Ltd
Priority to US08/010,786 priority Critical patent/USRE34698E/en
Application granted granted Critical
Publication of USRE34698E publication Critical patent/USRE34698E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Definitions

  • the present invention relates to an improvement in a method of producing polyether type antibiotics in an industrial scale.
  • Salinomycin 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8 substance are called Salinomycin type antibiotics because they have the similar chemical structures.
  • salinomycins means each compound, or any mixture of at least two compounds, selected from the group consisting of salinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6 and the like.
  • the present inventors already found that salinomycin, SY-1 and SY-2 were produced in the culture of Streptomyces albus waxman and henrich No. 80614 strain (FERM-P. No. 419), and succeeded in isolating the antibiotics from the culture (British Pat. No. 1378414, Japanese Unexamined Patent Publication No. 86191/1976 and Japanese Patent Application No. 5762/1977).
  • the inventors continued the study and found that, when the above strain is cultured in the medium containing fatty acid or its precursor, it produces salinomycin, SY-1, and SY-2 in high yield, and also produces new compounds such as SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8.
  • Another object of the present invention is to provide a method of producing Salinomycin type antibiotics such as salinomycin, 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8 substances in high yield.
  • Salinomycin type antibiotics such as salinomycin, 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8 substances in high yield.
  • salinomycin type antibiotics such as salinomycin, 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8 substances are produced by culturing a salinomycin type antibiotic-producing microorganism in a medium containing a fatty acid or its precursor and ammonia or an ammonium salt or urea.
  • the fatty acids used in the present invention are saturated or unsaturated fatty acids, for example, acetic acid, propionic acid, caproic acid, capric acid, palmitic acid, stearic acid, methacrylic acid, undecylic acid, and particularly linolic acid, linolenic acid or oleic acid being preferable.
  • the precursor of fatty acid means a substance that is capable of giving said fatty acid outside or inside the microorganism cell, such as mono-di- or triglycerides of fatty acid, esters of fatty acid or salts of fatty acid.
  • soy bean oil safflower oil, cotton seed oil, sesame oil, olive oil, rape oil, peanut oil, maize oil (corn oil), sunflower oil and like vegetable oils, code oil and like fish oils and lard and like animal fat-and-oils, which contain said precursors.
  • the esters of fatty acid can be C 1 -C 18 alcohols of said fatty acid.
  • the salts of fatty acid can be ammonium salt and alkali metal salts and alkaline earth metal salts of said fatty acid.
  • the addition amount is generally about 1-25%, particularly about 12-20% based on the medium.
  • Ammonia is used in gaseous form or in the form of aqueous solution.
  • ammonium salt there are used ammonium salts of inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid or organic acids such as acetic acid, propionic acid, higher fatty acid, oxalic acid, tartaric acid, hydrogentartaric acid, citric acid, lactic acid and malic acid.
  • the addition amount is generally about 0.1-1.0% particularly about 0.3-0.5% based on the medium.
  • addition is effective so long as production of potency of polyether type antibiotic continues, and is conducted at any time either before or after beginning of cultivation.
  • cultivation conditions of the present invention can be selected in accordance with the methods described in said known literatures, excepting that fatty acid or its precursor is used as major carbon source and that ammonia or ammonium salt is used as essential component of the medium, it is possible to raise the production efficiency by varying the conditions depending on the kind of antibiotics.
  • the microorganism used in the present invention include generally polyether type antibiotics producing strains belonging to the genus of Streptomyces as well as the strains described in said literatures and their natural or artificial mutants.
  • Separation and purification of the products can be carried out in accordance with known methods. Since the objective substance is often contained mainly in the solid portion containing the cells when the production amount of the objective substance is abundant, it is desirable to vary the extraction step properly in order to heighten the recovery percentage of the objective-substance from the solid portion. It is possible to use the objective compound in the state that it is contained in the solid portion depending on the use purposes, without separating the objective substance from the solid portion.
  • the production amount of polyether type antibiotics, particularly Salinomycin type antibiotics can be remarkably increased.
  • the yield of Salinomycin is generally 100-300 ⁇ /ml in known method, whereas the yield is about 10,000-20,000 ⁇ /ml in the medium containing fatty acid or its precursor, and the yield is further increased to about 50,000-80,000 ⁇ /ml when said medium is further added by ammonia or ammonium salt.
  • salinomycins mainly occur in the mycerial mass, at it is preferable to recover salinomycins from the mycelial mass.
  • another new compounds especially SY-3, SY-4, SY-5, SY-6, and the like are obtained from the culture.
  • the strains used in this invention include Streptomyces albus No. 80614 and its mutants artificially or naturally produced, as well as the other Streptomyces strains capable of producing salinomycins. However, some of the salinomycins can occasionally not be detected in the
  • Fermentation conditions employed in this invention can be any one commonly used for culturing Actinomycetes, except that main carbon source should be a fatty acid or its precursor.
  • Maximum production of salinomycins usually occurs after 150 to 260 hours from the start of fermentation. Ratio of each of salinomycins produced sometimes varies depending on the incubation time. Naturally, the composition of medium and fermentation conditions should be decided for each strain and external conditions, so that most desirable results are obtained.
  • Salinomycins can be isolated from the culture medium by utilizing the physico-chemical properties of salinomycins. Because salinomycins are structurally related to each other, the known extraction methods for salinomycin and SY-1 can be applied to the isolation of salinomycins, however, as for salinomycin, because a large portion of salinomycin is contained in mycelial mass, the extraction process is preferably modified so as to increase the recovery rate of salinomycin. For example, it is preferred to adjust the whole fermentation broth to pH 2.0-6.0 to precipitate salinomycin, and then to extract the mycerial mass together with the precipitate thus formed with an organic solvent.
  • the preferred solvents are acetone, ethyl acetate, butyl acetate, n-hexane, chloroform and the like.
  • the effluent is collected in 2-5 fractions according to the purpose. Separation and purification of salinomycins are effected by the procedures utilizing the difference between the properties of desired compound and impurities. Namely, chromatography, solvent extraction and the like are repeated for each fraction to give salinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7, SY-8, and the like, individually or as mixtures. The resulting products can be further purified by recrystallization or chromatography.
  • salinomycin, SY-1, and SY-2 especially salinomycin are obtained in surprisingly higher yield than the known process.
  • New compounds, SY-3 through -8 are also obtained according to this invention. They are comparable to salinomycin in their activities against microorganisms and useful as medicines. Also, because of their structural similarity to salinomycin, their usefulness as veterinary medicines looks very likely.
  • Streptomyces albus waxman and henrich No. 80614 strain (FERM-P. No. 419) is inoculated to a medium containing glycerine 2.0%, peptone 0.5% and meat extract 0.5% and cultured at 33° C. for 48 hours under shaking. 1 liter of this culture liquid is inoculated to 100 liters of liquid medium (200 liter tank made of stainless steel) containing glucose 2%, starch 1%, soy bean powder 2.5%, beer yeast 0.4%, meat extract 0.1%, sodium chloride 0.2% and antifoaming agent KM-68-2F (product of Shinetsu Chemical Industry Co., Ltd., silicone type) 0.1% and cultured at 33° C. for 144 hours under stirring with the aeration volume of 100 l/m. There is obtained a culture liquid containing 100-300 ⁇ /ml of Salinomycin.
  • the 80614 strain which is the same strain as described in Example 1 is inoculated to a medium containing glycerine 2.0%, peptone 0.25%, meat extract 0.5% and edible salt 0.1%, and cultured at 33° C. for 48 hours under shaking.
  • This culture liquid is an amount corresponding to 1% of the medium is inoculated to the medium containing glucose 4.0%, soy bean powder 1.0%, beer yeast 1.0% and calcium carbonate 0.2%, and cultured for 30 hours at 33° C. under shaking, and this culture liquid is made the second-stage pre-culture liquid.
  • One liter of this second-state preculture liquid is inoculated to 100 liters of liquid medium containing soy bean oil 10%, glucose 1.0%, soy bean powder 1.0%, calcium carbonate 0.5%, potassium secondary phosphate 0.01%, and cultured for 210 hours at 33° C. with an aeration volume of 100 l/m under stirring. There is obtained a culture liquid containing 20,000 ⁇ /ml of Salinomycin.
  • the 80614 strain which is the same strain as described in Example 1 is inoculated to a medium containing glycerine 2.0%, peptone 0.25%, meat extract 0.5% and edible salt 0.1%, and cultured at 33° C. for 48 hours under shaking.
  • This culture liquid in an amount corresponding to 1% of the medium is inoculated to the medium containing glucose 4.0%, soy bean powder 1.0%, beer yeast 1.0% and calcium carbonate 0.2%, and cultured for 30 hours at 33° C. under shaking, and this culture liquid is made the second-stage, pre-culture liquid.
  • This second-stage pre-culture liquid is inoculated to 100 liters of liquid medium containing soy bean oil 10%, glucose 1.0%, soy bean powder 1.0%, calcium carbonate 0.5%, potassium secondary phosphate 0.01%, and cultured for 210 hours at 33° C. with an aeration volume of 100 l/m under stirring. There is obtained a culture liquid containing 20,000 ⁇ /ml of salinomycin (salinomycin only).
  • the culture liquid obtained in (A) is adjusted to pH 4.5-5.0 with dilute hydrochloride, admixed with 4% by weight per volume of filter aid with stirring, and filtered.
  • the filtrate (80 liters) is extracted with 50 liters of butyl acetate with stirring.
  • Mycelial mass is extracted with 30 liters of butyl acetate.
  • Both butyl acetate solutions are combined and washed with 20 liters of 5% aqueous sodium bicarbonate solution.
  • One liter of the washed butyl acetate solution is concentrated under vacuum to dryness to give 250 g of crude powder of salinomycin containing trace amount of SY-1 and SY-2.
  • the almina column as mentioned above is further developed with a 100:15 mixture of ethyl acetate-methanol to elute SY-2, which is separated and purified by silica gel chromatography in the same manner as described above, and crystallized from acetone-water solution to give 3 mg of pure crystalline SY-2.
  • the culture obtained in (A) is adjusted to pH 4.5-5.0, heated at 60° C. for 10 minutes with stirring, admixed with 4% by weight per volume of filter aid with stirring and filtered.
  • the resulting mycelial mass contains salinomycins and SY group compounds in high yield.
  • Mycelial mass obtained in (B) is extracted twice with 50 liters of ethyl acetate. The extracts are combined and washed with 50 liters of 5% aqueous sodium bicarbonate solution. Ethyl acetate phase is concentrated under vacuum to dryness to yield 7 kg of crude salinomycins complex containing SY group compounds.
  • the mother liquor separated from the precipitate in the process in (A) is concentrated to dryness to give 4.6 kg of complex containing a small amount of salinomycin and SY group compounds.
  • the complex is dissolved in 50 liters of hexane-ethyl acetate solvent mixture (2:1) and applied to the column of 12 kg of almina packed in the same solvent system, developed with 20 liters of a 100:2 mixture of ethyl acetate-methanol to elute SY-3, SY-7 and salinomycin.
  • Two hundred g of the mixture of salinomycin and SY-1 is separated by precipitation in the same manner as described in (D).
  • the filtrate containing SY-3 and SY-7 is concentrated to dryness to give 100 g of crude powder.
  • the above almina column is eluted with 20 liters of a 5:1 mixture of ethyl acetate-methanol, and the effluent is concentrated under vacuum to give 200 g of crude powder, which contains the complex of SY-2, SY-4, SY-5, SY-6 and SY-8.
  • These compounds are isolated individually by silica gel column chromatography. Two hundred g of the crude powder is dissolved in 500 ml of a 100:2 mixture of chloroform-methanol, applied to the column of 2 kg silica gel (Wakogel C-200) packed in the same solvent mixture, and developed with the same solvent mixture to give each fraction containing SY-2, SY-4, SY-5, SY-6 and SY-8, respectively.
  • Example 1 The second-stage pre-culture liquid of Example 1 in an amount corresponding 10% of the medium is inoculated to the medium containing glucose 4%, soy bean powder 3%, defatted wheat germs 3.0%, calcium carbonate 0.2% and antifoaming agent KM-68-2F 0.1%, and cultured for 24 hours at 33° C. to give the third-stage pre-culture liquid.
  • Ten liters of the third-stage pre-culture liquid is inoculated to the medium containing soy bean oil 16%, soy bean powder 0.5%, defatted wheat germs 1.0%, sodium chloride 0.2%, potassium chloride 0.2%, ammonium sulfate 0.3%, calcium secondary phosphate 0.02%, magnesium sulfate 0.01% and antifoaming agent KM-68-2F 0.1%, and cultured for 290 hours at 33° C. with an aeration volume of 100 l/m under stirring.
  • the production amount of salinomycin at the end of cultivation is 60,000 ⁇ /ml (salinomycin only). In this case the similar production amount is attained even when soy bean oil is added in a small amount at the beginning and then the addition amount is increased. No difference in production amount is observed between cases in which silicone type and polyether type antifoaming agents are used.
  • the above almina column is eluted with 40 liters of a 5:1 mixture of ethyl acetate-methanol and the effluent is concentrated to dryness to give 250 g of crude powder containing the complex of SY-2, SY-4, SY-5, SY-6 and SY-7.
  • the complex is dissolved in 600 ml of chloroform-methanol solution (100:2), and then treated by chromatography (20 kg silica gel) in the same manner as described above to give 40 g of SY-2, 600 mg each of SY-4 and SY-5, 1900 mg of SY-6 and 300 mg of SY-8 as crude powders, purification of which according to the procedure of Example 2 (E) gives 30 g of crystallin SY-3, 180 mg of SY-4 powder, 120 mg of SY-5 powder, 350 mg of SY-6 powder and 90 mg of SY-8 powder, all in pure form.
  • the third-stage pre-culture liquid in Example 3 in an amount corresponding to 10% of the medium is inoculated to the medium (50 ml) containing each fat-and-oil shown in the following Table 12%, soy bean powder 0.5%, defatted wheat germs 1.0%, sodium chloride 0.2%, potassium chloride 0.2%, calcium carbonate 0.5%, ammonium solfate 0.3%, potassium secondary phosphate 0.02% and magnesium sulfate 0.01%, and cultured at 33° C. for 216 hours under shaking.
  • the production amounts of salinomycin at the end of cultivation are shown in the following Table.

Abstract

Polyether type antibiotics are produced by culturing a polyether type antibiotic-producing microorganism is a medium containing a fatty acid or its precursor and ammonia or an ammonium salt or urea.

Description

BACKGROUND OF THE INVENTION
The present invention relates to an improvement in a method of producing polyether type antibiotics in an industrial scale.
As polyether type antibiotic there have been known Monensin (Journal of American Chemical Society, Vo. 89, page 5757, 1967), X-206 (Chemical Communications, 927, 1971), Salinomycin (British Pat. No. 1,378,414), SY-1 substance (Japanese O.P.I. No. 86191/76), SY-2 substance (Japanese Patent Application No. 5762/77), 4-methylsalinomycin (A 28086 substance) (Japanese O.P.I. No. 9788/76), Lasalocid (Journal of American Chemical Society, Vol. 73, 5295, 1951), Dianemycin (Journal of Antibiotics, Vol. 22, page 161, 1969), Nigericin (Biochemical and Biophysical Research Communication, Vol. 33, page 29, 1968), A-204 A (Journal of American Chemical Society, Vol. 95, 3399, 1973) and the like, and among these, Salinomycin, 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8 substance are called Salinomycin type antibiotics because they have the similar chemical structures.
In this invention, the term "salinomycins" means each compound, or any mixture of at least two compounds, selected from the group consisting of salinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6 and the like.
The present inventors already found that salinomycin, SY-1 and SY-2 were produced in the culture of Streptomyces albus waxman and henrich No. 80614 strain (FERM-P. No. 419), and succeeded in isolating the antibiotics from the culture (British Pat. No. 1378414, Japanese Unexamined Patent Publication No. 86191/1976 and Japanese Patent Application No. 5762/1977).
The inventors continued the study and found that, when the above strain is cultured in the medium containing fatty acid or its precursor, it produces salinomycin, SY-1, and SY-2 in high yield, and also produces new compounds such as SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8.
As described in said literatures, these are produced by culturing each antibiotic producing microorganism belonging to the genus of Streptomyces. However, the yield of each antibiotic produced by such known method is not always satisfactory.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a method of producing polyether type antibiotics in remarkably high yields with industrial advantages.
Another object of the present invention is to provide a method of producing Salinomycin type antibiotics such as salinomycin, 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8 substances in high yield.
The foregoing and other objects of the present invention have been attained by culturing a polyether type antibiotic-producing microorganism in a medium containing a fatty acid or its precursor and ammonia or an ammonium salt or urea.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In the special feature of the present invention, salinomycin type antibiotics such as salinomycin, 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and SY-8 substances are produced by culturing a salinomycin type antibiotic-producing microorganism in a medium containing a fatty acid or its precursor and ammonia or an ammonium salt or urea.
The fatty acids used in the present invention are saturated or unsaturated fatty acids, for example, acetic acid, propionic acid, caproic acid, capric acid, palmitic acid, stearic acid, methacrylic acid, undecylic acid, and particularly linolic acid, linolenic acid or oleic acid being preferable. The precursor of fatty acid means a substance that is capable of giving said fatty acid outside or inside the microorganism cell, such as mono-di- or triglycerides of fatty acid, esters of fatty acid or salts of fatty acid. Further, there can be used soy bean oil, safflower oil, cotton seed oil, sesame oil, olive oil, rape oil, peanut oil, maize oil (corn oil), sunflower oil and like vegetable oils, code oil and like fish oils and lard and like animal fat-and-oils, which contain said precursors.
The esters of fatty acid can be C1 -C18 alcohols of said fatty acid.
The salts of fatty acid can be ammonium salt and alkali metal salts and alkaline earth metal salts of said fatty acid.
The addition amount is generally about 1-25%, particularly about 12-20% based on the medium.
Ammonia is used in gaseous form or in the form of aqueous solution. As ammonium salt there are used ammonium salts of inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid or organic acids such as acetic acid, propionic acid, higher fatty acid, oxalic acid, tartaric acid, hydrogentartaric acid, citric acid, lactic acid and malic acid. The addition amount is generally about 0.1-1.0% particularly about 0.3-0.5% based on the medium.
As for the time for addition of these additives, addition is effective so long as production of potency of polyether type antibiotic continues, and is conducted at any time either before or after beginning of cultivation. Although the cultivation conditions of the present invention can be selected in accordance with the methods described in said known literatures, excepting that fatty acid or its precursor is used as major carbon source and that ammonia or ammonium salt is used as essential component of the medium, it is possible to raise the production efficiency by varying the conditions depending on the kind of antibiotics.
The microorganism used in the present invention include generally polyether type antibiotics producing strains belonging to the genus of Streptomyces as well as the strains described in said literatures and their natural or artificial mutants.
Separation and purification of the products can be carried out in accordance with known methods. Since the objective substance is often contained mainly in the solid portion containing the cells when the production amount of the objective substance is abundant, it is desirable to vary the extraction step properly in order to heighten the recovery percentage of the objective-substance from the solid portion. It is possible to use the objective compound in the state that it is contained in the solid portion depending on the use purposes, without separating the objective substance from the solid portion.
According to the present invention the production amount of polyether type antibiotics, particularly Salinomycin type antibiotics can be remarkably increased. For example, the yield of Salinomycin is generally 100-300 γ/ml in known method, whereas the yield is about 10,000-20,000 γ/ml in the medium containing fatty acid or its precursor, and the yield is further increased to about 50,000-80,000 γ/ml when said medium is further added by ammonia or ammonium salt.
The preferable feature of the present invention to produce salinomycin type antibiotics will be further illustrated.
According to the method of this invention, salinomycins mainly occur in the mycerial mass, at it is preferable to recover salinomycins from the mycelial mass. In addition to salinomycin, SY-1, and SY-2, another new compounds, especially SY-3, SY-4, SY-5, SY-6, and the like are obtained from the culture.
The strains used in this invention include Streptomyces albus No. 80614 and its mutants artificially or naturally produced, as well as the other Streptomyces strains capable of producing salinomycins. However, some of the salinomycins can occasionally not be detected in the
__________________________________________________________________________
Characteristics of salinomycins                                           
Characteristics                                                           
        Rf values***                                                      
        Solvent system                m.sup.+.m/e                         
                                           antimicrobial                  
        CHCl.sub.3 2O                                                     
              EtOAc 4           Vanillin**                                
                                      (methyl                             
                                           activity***                    
Factor  MeOH 1                                                            
              (CH.sub.3).sub.2 CO 1                                       
                     EtOAc                                                
                         10% H.sub.2 SO*.sub.4                            
                                reagent                                   
                                      ester)                              
                                           100 γ/ml                 
                                                  Remarks                 
__________________________________________________________________________
SY-1    0.50  0.95   0.83                                                 
                         Yellow       748  21                             
Salinomycin                                                               
        0.40  0.90   0.60       Red   764  30                             
SY-2    0.35  0.35   0.15                                                 
                         Yellow 748    20                                 
SY-3    0.45  0.92   0.78                                                 
                         Yellow       748  28     (SY-1 analogue)         
SY-4    0.26  0.30   0.13       Red   764  25     (Salinomycin analogue)  
SY-5    0.17  0.19   0.10       Red   766  20     (18, 19-dihydrosalino-  
                                                  mycin analogue)         
SY-6    0.05  0.06   0.03       Red   782  15     (18, 19-dihydrosalino-  
                                                  mycin analogue)         
SY-7    0.80  0.98   0.95                                                 
                         Yellow            17     (SY-1 analogue)         
SY-8    0.11  0.13   0.06                                                 
                         Yellow            14     (SY-1 analogue)         
SY-1:   20-deoxy-salinomycin                                              
SY-2:   stereoisomer of SY-1                                              
SY-4:   5-hydroxy-salinomycin                                             
SY-5:   18, 19-dihydro-salinomycin                                        
SY-8:   stereoisomer of SY-5                                              
__________________________________________________________________________
 *Spray on silica gel plate (room temperature)                            
 **Dissolve 3 g of vanillin in 100 ml methanol. Add 0.5 ml of H.sub.2     
 SO.sub.4 with stirring. Spray on silica gel plate. Heat for 5 min at     
 60° C.                                                            
 ***Silica gel TLC (Wakogel B10, thickness 0.25 mm)                       
 ****diameter of inhibitory zone test organism: Batilus subtilis          
culture, depending on the strain and fermentation conditions.
Fermentation conditions employed in this invention can be any one commonly used for culturing Actinomycetes, except that main carbon source should be a fatty acid or its precursor. Maximum production of salinomycins usually occurs after 150 to 260 hours from the start of fermentation. Ratio of each of salinomycins produced sometimes varies depending on the incubation time. Naturally, the composition of medium and fermentation conditions should be decided for each strain and external conditions, so that most desirable results are obtained.
Salinomycins can be isolated from the culture medium by utilizing the physico-chemical properties of salinomycins. Because salinomycins are structurally related to each other, the known extraction methods for salinomycin and SY-1 can be applied to the isolation of salinomycins, however, as for salinomycin, because a large portion of salinomycin is contained in mycelial mass, the extraction process is preferably modified so as to increase the recovery rate of salinomycin. For example, it is preferred to adjust the whole fermentation broth to pH 2.0-6.0 to precipitate salinomycin, and then to extract the mycerial mass together with the precipitate thus formed with an organic solvent. Among the preferred solvents are acetone, ethyl acetate, butyl acetate, n-hexane, chloroform and the like. After applying the solution to the absorptive materials suitable for the absorption of salinomycins, the salinomycins are eluted by a suitable solvent system.
the effluent is collected in 2-5 fractions according to the purpose. Separation and purification of salinomycins are effected by the procedures utilizing the difference between the properties of desired compound and impurities. Namely, chromatography, solvent extraction and the like are repeated for each fraction to give salinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7, SY-8, and the like, individually or as mixtures. The resulting products can be further purified by recrystallization or chromatography.
The properties of salinomycins obtained by the process of this invention are shown in the following table.
According to the preferred feature of this invention salinomycin, SY-1, and SY-2, especially salinomycin are obtained in surprisingly higher yield than the known process. New compounds, SY-3 through -8 are also obtained according to this invention. They are comparable to salinomycin in their activities against microorganisms and useful as medicines. Also, because of their structural similarity to salinomycin, their usefulness as veterinary medicines looks very likely.
REFERENCE EXAMPLE 1
Streptomyces albus waxman and henrich No. 80614 strain (FERM-P. No. 419) is inoculated to a medium containing glycerine 2.0%, peptone 0.5% and meat extract 0.5% and cultured at 33° C. for 48 hours under shaking. 1 liter of this culture liquid is inoculated to 100 liters of liquid medium (200 liter tank made of stainless steel) containing glucose 2%, starch 1%, soy bean powder 2.5%, beer yeast 0.4%, meat extract 0.1%, sodium chloride 0.2% and antifoaming agent KM-68-2F (product of Shinetsu Chemical Industry Co., Ltd., silicone type) 0.1% and cultured at 33° C. for 144 hours under stirring with the aeration volume of 100 l/m. There is obtained a culture liquid containing 100-300 γ/ml of Salinomycin.
REFERENCE EXAMPLE 2
The 80614 strain which is the same strain as described in Example 1 is inoculated to a medium containing glycerine 2.0%, peptone 0.25%, meat extract 0.5% and edible salt 0.1%, and cultured at 33° C. for 48 hours under shaking.
This culture liquid is an amount corresponding to 1% of the medium is inoculated to the medium containing glucose 4.0%, soy bean powder 1.0%, beer yeast 1.0% and calcium carbonate 0.2%, and cultured for 30 hours at 33° C. under shaking, and this culture liquid is made the second-stage pre-culture liquid. One liter of this second-state preculture liquid is inoculated to 100 liters of liquid medium containing soy bean oil 10%, glucose 1.0%, soy bean powder 1.0%, calcium carbonate 0.5%, potassium secondary phosphate 0.01%, and cultured for 210 hours at 33° C. with an aeration volume of 100 l/m under stirring. There is obtained a culture liquid containing 20,000 γ/ml of Salinomycin.
EXAMPLE 1
(A) Production of salinomycin
The 80614 strain which is the same strain as described in Example 1 is inoculated to a medium containing glycerine 2.0%, peptone 0.25%, meat extract 0.5% and edible salt 0.1%, and cultured at 33° C. for 48 hours under shaking. This culture liquid in an amount corresponding to 1% of the medium is inoculated to the medium containing glucose 4.0%, soy bean powder 1.0%, beer yeast 1.0% and calcium carbonate 0.2%, and cultured for 30 hours at 33° C. under shaking, and this culture liquid is made the second-stage, pre-culture liquid. One liter of this second-stage pre-culture liquid is inoculated to 100 liters of liquid medium containing soy bean oil 10%, glucose 1.0%, soy bean powder 1.0%, calcium carbonate 0.5%, potassium secondary phosphate 0.01%, and cultured for 210 hours at 33° C. with an aeration volume of 100 l/m under stirring. There is obtained a culture liquid containing 20,000 γ/ml of salinomycin (salinomycin only).
(B) Separation and purification of salinomycin, SY-1 and SY-2.
The culture liquid obtained in (A) is adjusted to pH 4.5-5.0 with dilute hydrochloride, admixed with 4% by weight per volume of filter aid with stirring, and filtered. The filtrate (80 liters) is extracted with 50 liters of butyl acetate with stirring. Mycelial mass is extracted with 30 liters of butyl acetate. Both butyl acetate solutions are combined and washed with 20 liters of 5% aqueous sodium bicarbonate solution. One liter of the washed butyl acetate solution is concentrated under vacuum to dryness to give 250 g of crude powder of salinomycin containing trace amount of SY-1 and SY-2.
Fifty grams of the crude salinomycin powder is dissolved in ethyl acetate and applied to column (50 g of active almina, commercial product of Wako Junyaku Co.). After washing the column with one liter of ethyl acetate, salinomycin and SY-1 are eluted with a 100:5 mixture of ethyl acetate-methanol solution. The fractions containing salinomycin and SY-1 are combined and concentrated. The concentrate is diluted in 50 ml of chloroform-methand solution (100:2) and applied to the column of 300 g silica gel (Wakogel-200, Wako Junyaku Co.) packed in the same solvent mixture. Elution is carried out with the same solvent mixture to give pure salinomycin fraction and pure SY-1 fraction. Each fraction is concentrated and crystallized from acetone-water solution to give 5 g of salinomycin and 30 mg of SY-1 in pure crystals, respectively.
The almina column as mentioned above is further developed with a 100:15 mixture of ethyl acetate-methanol to elute SY-2, which is separated and purified by silica gel chromatography in the same manner as described above, and crystallized from acetone-water solution to give 3 mg of pure crystalline SY-2.
EXAMPLE 2
(A) Salinomycin is cultured in the same manner as described in Example 1.
(B) Recovery of salinomycins
The culture obtained in (A) is adjusted to pH 4.5-5.0, heated at 60° C. for 10 minutes with stirring, admixed with 4% by weight per volume of filter aid with stirring and filtered. The resulting mycelial mass contains salinomycins and SY group compounds in high yield.
(C) Separation of salinomycins complex
Mycelial mass obtained in (B) is extracted twice with 50 liters of ethyl acetate. The extracts are combined and washed with 50 liters of 5% aqueous sodium bicarbonate solution. Ethyl acetate phase is concentrated under vacuum to dryness to yield 7 kg of crude salinomycins complex containing SY group compounds.
(D) Separation and purification salinomycin
Seven kg of crude powder obtained in (C) is dissolved in 100 liters of hexane, concentrated under vacuum to 20 liters and left at 5° C. to give 2.7 kg of crude crystallin salinomycin. After repeating this procedure, recrystallization of salinomycin from hexane gives 2.4 kg of pure salinomycin sodium salt.
(E) Separation and purification of SY group compounds
The mother liquor separated from the precipitate in the process in (A) is concentrated to dryness to give 4.6 kg of complex containing a small amount of salinomycin and SY group compounds. The complex is dissolved in 50 liters of hexane-ethyl acetate solvent mixture (2:1) and applied to the column of 12 kg of almina packed in the same solvent system, developed with 20 liters of a 100:2 mixture of ethyl acetate-methanol to elute SY-3, SY-7 and salinomycin. Two hundred g of the mixture of salinomycin and SY-1 is separated by precipitation in the same manner as described in (D). The filtrate containing SY-3 and SY-7 is concentrated to dryness to give 100 g of crude powder.
One hundred g of crude powder thus obtained is dissolved in 300 ml of a 100:2 mixture of chloroform-methanol and applied to the column of 6 kg of silica gel (Wakogel C-200, Wako Junyaku Co.), and developed with the same solvent mixture. Each of SY-3 and SY-7 fractions is concentrated and applied to silica gel thin layer chromatogram (Wakogel B-10 with thickness of 0.25 mm, solvent system; a 20:1 mixture of chloroform-methanol). SY-3 and SY-7 are collected by scraping off the areas with Rf values 0.45 and 0.80, respectively. The silica gel holding each compound is eluted with a 20:1 mixture of chloroform-methanol and the solvent mixture is removed by evaporation to give 18 mg of SY-3 and 35 mg of SY-7 both in pure powders.
The above almina column is eluted with 20 liters of a 5:1 mixture of ethyl acetate-methanol, and the effluent is concentrated under vacuum to give 200 g of crude powder, which contains the complex of SY-2, SY-4, SY-5, SY-6 and SY-8. These compounds are isolated individually by silica gel column chromatography. Two hundred g of the crude powder is dissolved in 500 ml of a 100:2 mixture of chloroform-methanol, applied to the column of 2 kg silica gel (Wakogel C-200) packed in the same solvent mixture, and developed with the same solvent mixture to give each fraction containing SY-2, SY-4, SY-5, SY-6 and SY-8, respectively. Each fraction is concentrated to dryness to give 20 g of SY-2, 300 mg of SY-4, 250 mg of SY-5, 800 mg of SY-6 and 100 mg of SY-8 as crude powders, respectively. Crude SY-2 powders are crystallized from acetone water to give 15 g of pure crystalline SY-2.
Other crude powders are purified by thin layer chromatography of silica gel in the same manner as employed in the separation and purification of SY-3 and SY-7 to give 26 mg of SY-4, 20 mg of SY-5, 80 mg of SY-6 and 30 mg of SY-8 each in pure powders.
EXAMPLE 3
(A) The second-stage pre-culture liquid of Example 1 in an amount corresponding 10% of the medium is inoculated to the medium containing glucose 4%, soy bean powder 3%, defatted wheat germs 3.0%, calcium carbonate 0.2% and antifoaming agent KM-68-2F 0.1%, and cultured for 24 hours at 33° C. to give the third-stage pre-culture liquid.
Ten liters of the third-stage pre-culture liquid is inoculated to the medium containing soy bean oil 16%, soy bean powder 0.5%, defatted wheat germs 1.0%, sodium chloride 0.2%, potassium chloride 0.2%, ammonium sulfate 0.3%, calcium secondary phosphate 0.02%, magnesium sulfate 0.01% and antifoaming agent KM-68-2F 0.1%, and cultured for 290 hours at 33° C. with an aeration volume of 100 l/m under stirring. The production amount of salinomycin at the end of cultivation is 60,000 γ/ml (salinomycin only). In this case the similar production amount is attained even when soy bean oil is added in a small amount at the beginning and then the addition amount is increased. No difference in production amount is observed between cases in which silicone type and polyether type antifoaming agents are used.
(B) Treat the fermentation broth obtained in (A) according to the procedure of Example 2 (B) to give mycelial mass containing salinomycins in high yield.
(C) Treat the mycelial mass obtained in (B) according to the procedure of Example 2 (C) to give 16 kg of the complex of SY-1, 2, 3, 4, 5, 6, 7 and 8.
(D) Dissolve 16 kg of crude powder obtained in (C) in 100 liters of hexane and concentrate under vacuum to 40 liters. Then treat the solution according to the same procedure described in Example 2 (D) to give 7.1 kg of crude crystallin salinomycin and then 6.3 kg of pure salinomycin sodium salt.
(E) The mother liquor separated from crystals in the process in (D) is concentrated to dryness to give 9.7 kg of the complex containing SY-1 through -8. The complex is dissolved in 100 liters of a 2:1 mixture of hexane-ethyl acetate, applied to the column of 20 kg of almina in the same manner as described in Example 2 (E) and developed with 30 liters of a 100:2 mixture of ethyl acetate-methanol to elute SY-1, SY-3 and SY-7. The effluent is treated in the same manner as described in Example 2 (E) to give 400 g of salinomycin-SY-1 mixture and 130 g of crude powder containing SY-3 and SY-7.
One hundred and thirty g of said crude powder is dissolved in 400 ml of chloroform-methanol solution (100:2), treated by silica gel column chromatography (8 kg of silica gel is used) to give SY-3-and SY-7-fractions. Each fraction is chromatographed over silica gel thin layer according to Example 2 (E), and after removing the solvent by evaporation, 30 mg of SY-3 and 50 mg of SY-7 are obtained as pure powders.
The above almina column is eluted with 40 liters of a 5:1 mixture of ethyl acetate-methanol and the effluent is concentrated to dryness to give 250 g of crude powder containing the complex of SY-2, SY-4, SY-5, SY-6 and SY-7. The complex is dissolved in 600 ml of chloroform-methanol solution (100:2), and then treated by chromatography (20 kg silica gel) in the same manner as described above to give 40 g of SY-2, 600 mg each of SY-4 and SY-5, 1900 mg of SY-6 and 300 mg of SY-8 as crude powders, purification of which according to the procedure of Example 2 (E) gives 30 g of crystallin SY-3, 180 mg of SY-4 powder, 120 mg of SY-5 powder, 350 mg of SY-6 powder and 90 mg of SY-8 powder, all in pure form.
EXAMPLE 4
The third-stage pre-culture liquid in Example 3 in an amount corresponding to 10% of the medium is inoculated to the medium (50 ml) containing each fat-and-oil shown in the following Table 12%, soy bean powder 0.5%, defatted wheat germs 1.0%, sodium chloride 0.2%, potassium chloride 0.2%, calcium carbonate 0.5%, ammonium solfate 0.3%, potassium secondary phosphate 0.02% and magnesium sulfate 0.01%, and cultured at 33° C. for 216 hours under shaking. The production amounts of salinomycin at the end of cultivation are shown in the following Table.
______________________________________                                    
                Yield of                                                  
Fat-and-oil     salinomycin (γ/ml)                                  
______________________________________                                    
soy bean oil    38000                                                     
purified soy bean oil                                                     
                36000                                                     
(Shirashime oil)                                                          
Sesame oil      36000                                                     
rape oil        35000                                                     
safflower oil   39000                                                     
olive oil       37000                                                     
cod oil         37000                                                     
methyl oleate   34000                                                     
methyl myristate                                                          
                38000                                                     
methyl linolate 38000                                                     
______________________________________                                    
From the resulting culture, salinomycins are separated individually and purified according to the procedures of Examples 1-3.

Claims (4)

What is claimed is:
1. A method of producing salinomycins, which comprises culturing a salinomycins-producing Streptomyces microorganism in a medium containing .Iadd.12-25% .Iaddend.fatty acid or its precursor and ammonia or an ammonium salt and recovering the salinomycins from the culture.
2. The method of claim 1 wherein salinomycin is recovered together with the mycelial mass from the culture.
3. The method of claim 1 or 2 wherein SY-1, SY-2, SY-3, SY-4, SY-5, and/or SY-6 is recovered from the culture.
4. The method of claim 1, wherein salinomycin, 4-methylsalinomycin, SY-1, SY-2, SY-3, SY-4, SY-5, SY-6, SY-7 and/or SY-8 is recovered from the culture.
US08/010,786 1977-05-31 1993-01-29 Method of producing salinomycin antibiotics Expired - Lifetime USRE34698E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/010,786 USRE34698E (en) 1977-05-31 1993-01-29 Method of producing salinomycin antibiotics

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP52062802A JPS6038115B2 (en) 1977-05-31 1977-05-31 Manufacturing method for polyether antibiotics
JP52-62802 1977-05-31
JP52-63215 1977-06-01
JP6321577A JPS53148595A (en) 1977-06-01 1977-06-01 Preparation of salinomycines
US05/911,231 US4212942A (en) 1977-05-31 1978-05-31 Method of producing salinomycin antibiotics
US08/010,786 USRE34698E (en) 1977-05-31 1993-01-29 Method of producing salinomycin antibiotics

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US05/911,231 Reissue US4212942A (en) 1977-05-31 1978-05-31 Method of producing salinomycin antibiotics

Publications (1)

Publication Number Publication Date
USRE34698E true USRE34698E (en) 1994-08-16

Family

ID=26403860

Family Applications (2)

Application Number Title Priority Date Filing Date
US05/911,231 Ceased US4212942A (en) 1977-05-31 1978-05-31 Method of producing salinomycin antibiotics
US08/010,786 Expired - Lifetime USRE34698E (en) 1977-05-31 1993-01-29 Method of producing salinomycin antibiotics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US05/911,231 Ceased US4212942A (en) 1977-05-31 1978-05-31 Method of producing salinomycin antibiotics

Country Status (3)

Country Link
US (2) US4212942A (en)
AU (1) AU516543B2 (en)
IT (1) IT1096401B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU516543B2 (en) * 1977-05-31 1981-06-11 Kaken Chemical Co. Ltd. Polyether type antibiotics
US4564594A (en) * 1983-06-30 1986-01-14 E. I. Du Pont De Nemours And Company Fermentation process for production of carboxylic acids
US5041374A (en) * 1986-05-29 1991-08-20 International Minerals & Chemical Corp. Polyether antibiotic recovery and purification
US5047338A (en) * 1986-05-29 1991-09-10 International Minerals & Chemical Corp. Polyester Antibiotic preparation
US5049495A (en) * 1986-05-29 1991-09-17 International Minerals & Chemical Corp. Fermentation method for producing polyether antibiotics
US5278053A (en) * 1991-09-16 1994-01-11 Eli Lilly And Company Method of producing a polyether antibiotic from actinomadura fibrosa sp. nov. NRRL 18348 and actinomadura sp. NRRL 18880

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1378414A (en) * 1972-10-31 1974-12-27 Keken Chemical Co Ltd Antibiotic compound and its preparation
US4035481A (en) * 1975-04-21 1977-07-12 Eli Lilly And Company Antibiotic A-28086 and process for production thereof
US4212942A (en) * 1977-05-31 1980-07-15 Kaken Chemical Company, Limited Method of producing salinomycin antibiotics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1378414A (en) * 1972-10-31 1974-12-27 Keken Chemical Co Ltd Antibiotic compound and its preparation
US4035481A (en) * 1975-04-21 1977-07-12 Eli Lilly And Company Antibiotic A-28086 and process for production thereof
US4212942A (en) * 1977-05-31 1980-07-15 Kaken Chemical Company, Limited Method of producing salinomycin antibiotics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
W. M. Stark, Monensis, A Biologically Active Compound, Fermentation Advances, Academic Press, 1969, pp. 517 540. *
W. M. Stark, Monensis, A Biologically Active Compound, Fermentation Advances, Academic Press, 1969, pp. 517-540.

Also Published As

Publication number Publication date
IT7824041A0 (en) 1978-05-31
AU3666278A (en) 1979-12-06
US4212942A (en) 1980-07-15
IT1096401B (en) 1985-08-26
AU516543B2 (en) 1981-06-11

Similar Documents

Publication Publication Date Title
US4375464A (en) Antibiotic AY24,668 and process of preparation
USRE34698E (en) Method of producing salinomycin antibiotics
EP0339681B1 (en) Antitumor antibiotic substance
EP0000037B1 (en) Method of producing salinomycin type antibiotics and new salinomycin type antibiotics
DE2849696A1 (en) METHOD OF MANUFACTURING ANTIBIOTIC C-15003 P-3
US3855200A (en) Process for preparing 8-hydroxyerthromycin a and intermediates therefor
EP0322630B1 (en) Process for the preparation of pregneno-oxazolines
DD202047A5 (en) PROCESS FOR PREPARING THE MAKROLIDE 20-DIHYDRO-20,23-DIDEOXYTYLONOLIDE
EP0652205A2 (en) Moenomycin degradation products containing hydroxylated or oxidized lateral lipid chain and moenomycin analogs, process for preparing and their use
DE2014277C3 (en) Process for the preparation of acyl derivatives of the antibiotic T-2636 C
DE1909152C3 (en) Microbiological process for the production of 11 a-hydroxy-3-oxo-8I4-steroids "of the pregnane and androstane series
CH640269A5 (en) Method for producing the antibiotic c-15003 p. 4
EP0046641B1 (en) Novel antibiotics, the microbiological preparation of antibiotics, and a novel microorganism
US4036876A (en) 18- AND 19-Hydroxylated prostaglandins
DE3407979C2 (en)
US2916483A (en) Methymycin
US3950516A (en) Process for preparing cirramycin A1
EP0260486B1 (en) Pharmacologically active phenoxazinones, process for their preparation and their use
US5001258A (en) Antibiotic, fumifungin, a microbial process for the preparation thereof, and the use thereof as a pharmaceutical
DE2921052C2 (en)
US4753959A (en) Antibiotic lactone compound
EP0272605A2 (en) Process for the preparation of derivatives of optically active 2-hydroxy-butyric acid
DE2248793C3 (en) Process for the manufacture of macrolide antibiotics
DE2261832C3 (en) 5-Dihydrocoriolin C and process for its preparation
DE1492111C (en) Process for the production of poly oxm A and B.